Less than a year into their drug development partnership, privately held Edison Pharmaceuticals Inc. and Japan’s Dainippon Sumitomo Pharma Co. Ltd. (DSP) bulked up the deal, inking a potential $4.295 billion strategic alliance that vastly expands their pursuit of drugs targeting cellular energy metabolism.